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Summarising and validating test
accuracy results across multiple studies
for use in clinical practice
Richard D. Riley,a*† Ikhlaaq Ahmed,b
Thomas P. A. Debray,c Brian H. Willis,d J. Pieter Noordzij,e
Julian P.T. Higginsf and Jonathan J. Deeksd
Following a meta-analysis of test accuracy studies, the translation of summary results into clinical practice is
potentially problematic. The sensitivity, specificity and positive (PPV) and negative (NPV) predictive values of a
test may differ substantially from the average meta-analysis findings, because of heterogeneity. Clinicians thus
need more guidance: given the meta-analysis, is a test likely to be useful in new populations, and if so, how should
test results inform the probability of existing disease (for a diagnostic test) or future adverse outcome (for a prog-
nostic test)? We propose ways to address this. Firstly, following a meta-analysis, we suggest deriving prediction
intervals and probability statements about the potential accuracy of a test in a new population. Secondly, we sug-
gest strategies on how clinicians should derive post-test probabilities (PPV and NPV) in a new population based
on existing meta-analysis results and propose a cross-validation approach for examining and comparing their
calibration performance. Application is made to two clinical examples. In the first example, the joint probabil-
ity that both sensitivity and specificity will be >80% in a new population is just 0.19, because of a low sensitivity.
However, the summary PPV of 0.97 is high and calibrates well in new populations, with a probability of 0.78 that
the true PPV will be at least 0.95. In the second example, post-test probabilities calibrate better when tailored to
the prevalence in the new population, with cross-validation revealing a probability of 0.97 that the observed NPV
will be within 10% of the predicted NPV. © 2015 The Authors. Statistics in Medicine Published by John Wiley &
Sons Ltd.
Keywords: meta-analysis; test accuracy; prognostic; diagnostic; calibration; discrimination
1. Introduction
Test accuracy studies aim to evaluate the performance of a candidate medical test for either diagnosing
the presence of a particular clinical condition (‘diagnostic test’) or identifying those likely to experi-
ence a particular outcome in the future (‘prognostic test’). Such tests include measurable variables such
as biomarkers, blood pressure and temperature, or may reflect a clinician’s judgement after a physical
examination or imaging result. When multiple studies evaluate the performance of a potential diagnostic
or prognostic test, meta-analysis methods can synthesise the study results to help establish if and how
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the test can be used in practice [1–4]. Current meta-analyses of test accuracy studies focus on producing
pooled estimates that summarise average test performance across the multiple studies [2–6]. This typi-
cally leads to a single pooled estimate for each of sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) and sometimes a summary ROC curve. For example, in patients
undergoing a thyroidectomy, Noordzij et al. [7] examine the accuracy of the % change in parathyroid
(PTH) levels (from pre-surgery to post-surgery) for identifying those at high risk of becoming hypocal-
cemic within 48 h. They synthesise data from six studies and summarise that a 70% or greater reduction
in PTH has a sensitivity of 0.93, a specificity of 0.88, a PPV of 0.74 and an NPV of 0.97. However,
when data are available from multiple studies, a major concern is heterogeneity in test accuracy, which
refers to genuine differences in the accuracy of a test from study to study. Heterogeneity in test accu-
racy is common in meta-analysis and is caused by study differences in, for example, clinical settings
(such as hospitals), patient selection (such as symptom severity and previous testing), choice of health-
care practitioners implementing/reading the test, the included patient populations (e.g. with a different
underlying prevalence of disease) and the test methodology employed (e.g. choice of threshold, method
of measurement and the reference standard).
Where heterogeneity exists, this is usually accounted for by using random-effects models that allow
test accuracy to vary across studies [2, 4]. However, typically, the aim of meta-analysis is as before: to
estimate the average test performance across all the populations included. Although this is a worthwhile
research question, the translation of such averagemeta-analysis results into clinical practice is potentially
problematic. For example, a diagnostic test may have high sensitivity and specificity values on average,
but the causes of heterogeneity may lead to substantially lower values in some particular populations,
leading to poor performance. Similarly, average post-test probabilities from a prognostic test may be
inaccurate, for example, if the outcome prevalence in a particular population is markedly different than
the average outcome prevalence across all populations. For example, Leeflang et al. [5] said ‘when a
review contains studies with a broad range of prevalence, there will be difficulties in working out how
the average predictive values (estimated for the average included study with an average prevalence) can
be applied in clinical practice.’
To address this concern, this article suggests ways to improve the translation of meta-analysis results
for clinical practice, by going beyond presenting just average test accuracy results. There are two main
objectives. Firstly, we emphasise the importance of deriving and reporting prediction intervals for the
potential accuracy of a test in a new population [8,9]. Secondly, we propose a cross-validation approach
for examining how to derive PPV and NPV in new populations based on existing meta-analysis results.
Our viewpoint is similar to Willis and Hyde [10], who propose that meta-analysis results need to be
tailored before use in a particular population, and Leeflang et al. [5], who propose predicting PPV and
NPV in new populations. Our cross-validation framework provides a way to examine the calibration of
approaches (or statistical equations) that tailor (or predict) results for new populations.
The remainder of the paper is as follows. In Section 2, we introduce two motivating datasets that are
used throughout the article. Section 3 introduces the derivation and interpretation of prediction intervals
(regions) following meta-analysis, in terms of the discrimination ability of a test (sensitivity, specificity
and c statistic). Section 4 suggests approaches to derive PPV andNPV in new populations and outlines the
cross-validation framework for examining their calibration. Section 5 considers extension to comparing
tests. Section 6 provides some discussion, and Section 7 concludes.
2. Motivating datasets
2.1. Accuracy of ear temperature for diagnosing fever in children
Craig et al. [11] systematically reviewed thermometry studies comparing temperatures taken at the ear
and rectum in children, and of clinical interest is the accuracy of infrared ear thermometry for diagnos-
ing fever [12]. Eleven studies (involving 2323 children) evaluated the accuracy of a ‘FirstTemp’ branded
ear thermometer in relation to an electronic rectal thermometer. Rectal temperature was the reference
measure, as it is a well-established method of measuring temperature in children, and it guides clinical
decisions and the definition of fever. However, measuring temperature at the ear is clearly more accept-
able than measuring temperature at the rectum, and so ear measurements would be preferable if their
diagnostic accuracy is adequate. All studies defined patients with an ear temperature ⩾38.0 °C to be test
positive, and the gold standard definition of fever was a rectal temperature ⩾38.0 °C (Table I), consis-
tent with National Health Service guidelines for diagnosing fever in children at the time of these studies.
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Table I. Summary of the 11 temperature studies identified for meta-analysis;
each study used a threshold of 38 °C to define fever, an electronic rectal
thermometer and a FirstTemp ear thermometer.
Observed
First author r11i n1i Sensitivity r00i n0i Specificity prevalence
Brennan 150 203 0.74 155 167 0.93 0.55
Davis 9 18 0.50 46 48 0.96 0.27
Green 8 9 0.89 12 12 1.00 0.43
Greenes 53 109 0.49 193 195 0.99 0.36
Hoffman 30 42 0.71 56 58 0.97 0.42
Hooker 10 15 0.67 24 24 1.00 0.38
Lanham 53 103 0.51 74 75 0.99 0.58
Muma 48 87 0.55 136 136 1.00 0.39
Nypaver 282 425 0.66 445 453 0.98 0.48
Rhoads 7 27 0.26 38 38 1.00 0.42
Stewart 57 59 0.97 20 20 1.00 0.75
r11i, number of true positives; n1i, number with fever.
r00i, number of true negatives; n0i, number without fever.
Table II. Summary of five cohort studies evaluating the accuracy of a >65% change
in PTH (measured pre-operation to 0–20 min post-thyroidectomy) for identifying
hypocalcaemia.
Observed proportion
First author r11i n1i Sensitivity r00i n0i Specificity with outcome
Lo 11 11 1.0 56 89 0.63 0.11
Lombardi 13 16 0.81 31 35 0.89 0.31
McLeod 9 13 0.69 33 43 0.77 0.23
Warren, 2002 3 4 0.75 10 12 0.83 0.25
Warren, 2004 2 3 0.67 20 23 0.87 0.12
r11i, number of true positives; n1i, number with hypocalcaemia.
r00i, number of true negatives; n0i, number without for identifying hypocalcaemia.
PTH, parathyroid.
Table III. Summary of five cohort studies evaluating the accuracy of a >65% change
in PTH (measured pre-operation to 1–2 h post-thyroidectomy) for identifying hypocal-
caemia.
Observed proportion
First author r11i n1i Sensitivity r00i n0i Specificity with outcome
Lam 12 12 1.0 24 26 0.92 0.32
Lombardi 15 16 0.94 29 35 0.83 0.31
McLeod 11 12 0.92 19 25 0.76 0.32
Warren, 2002 1 2 0.50 6 8 0.75 0.2
Warren, 2004 3 3 1.0 17 23 0.74 0.12
r11i, number of true positives; n1i, number with hypocalcaemia.
r00i, number of true negatives; n0∖i, number without hypocalcaemia.
PTH, parathyroid.
The studies included children already in hospital or attending accident and emergency [11], and so the
observed prevalence of fever was high, around 50%. The summary results for each study are shown in
Table I in terms of the totals with and without fever, estimated sensitivity and specificity and the number
of true positives and negatives. Meta-analysis is required to summarise test accuracy across these stud-
ies, to appropriately quantify any between-study heterogeneity in test accuracy and – most important to
this article – to identify the potential performance of the test in new populations.
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2015, 34 2081–2103
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2.2. Accuracy of % change in PTH for predicting risk of hypocalcaemia
As mentioned, Noordzij et al. [7] examined the accuracy of the % change in PTH for identifying patients
at high risk of becoming hypocalcemic within 48 h after a thyroidectomy. The % change from baseline
(rather than absolute change) was used to minimise the impact of different methods of measuring PTH
across studies. We focus here on the accuracy of PTH when using a threshold of 65%, above which a
patient is classed as test positive. Table II summarises the test accuracy results for five cohort studies for
% change in PTH when measured from baseline (before surgery) to 0–20 min post-surgery. Similarly,
Table III summarises the five cohort studies evaluating% change in PTHwhenmeasured from baseline to
1–2 h post-surgery. Meta-analysis results are important here to inform whether PTH can suitably identify
those at high risk of hypocalcaemia (to ensure they remain in hospital) and those at low risk of hypocal-
caemia (who may therefore benefit from early hospital discharge). If PTH appears useful, understanding
how best to translate the meta-analysis results into clinical practice is then crucial.
3. Examining and summarising the discrimination of a test using meta-analysis
Discrimination statistics, such as sensitivity and specificity, quantify how a test distinguishes between
patients with and without the disease (or outcome) of interest and are thus conditional on knowing true
disease status. In this section, we show how to use meta-analysis results for predicting a test’s discrim-
ination performance in a new population. For simplicity, we refer only to diagnostic tests, but the same
principles apply for prognostic test studies where outcome status is known for all patients by a given time.
3.1. Sensitivity and specificity
3.1.1. Bivariate meta-analysis model. Suppose there are k test accuracy studies (indexed by i , where
i = 1 to k) including n1i and n0i patients with and without disease, respectively. The test classifies each
patient as either positive or negative, with the aim that those positive are truly diseased and those negative
are truly non-diseased. Summarising test results over all patients in each study produces aggregate data
in the form of r11i (true positives), the number of patients in study i with a positive test result who truly
have the disease, and r00i (true negatives), the number of patients in study i with a negative test result
who truly do not have the disease (true negatives). The observed sensitivity in each study is r11i∕n1i, and
the observed specificity is r00i∕n0i. In this situation, a bivariate random-effects meta-analysis can jointly
synthesise sensitivity and specificity across studies [2, 3], with r11i and r00i modelled directly using the
binomial distribution [4, 13] and allowing for potential between-study heterogeneity in logit-sensitivity
and logit-specificity, and their potential between-study correlation due to explicit and implicit differences
in threshold value across studies [2].
r11i ∼ Binomial
(
n1i, p1i
)
r00i ∼ Binomial
(
n0i, p0i
)(
logit
(
p1i
)
logit
(
p0i
)
)
∼ N
[(
𝛽1
𝛽0
)
, 𝛀
]
, 𝛀 =
(
𝜏21 𝜏1𝜏0𝜌
𝜏1𝜏0𝜌 𝜏
2
0
) (1)
Model (1) specifies an underlying logit-sensitivity and logit-specificity in each study, by logit(p1i) and
logit(p0i), respectively, which are assumed normally distributed about a mean logit-sensitivity of 𝛽1
and a mean logit-specificity of 𝛽0, with between-study variances 𝜏
2
1 and 𝜏
2
0 , respectively, and between-
study correlation 𝜌. Estimation of model (1) is possible in both frequentist and Bayesian frameworks,
using maximum likelihood estimation via Gaussian quadrature [4, 14–16] or MCMC estimation using
Gibbs sampling, respectively [17–20]. For brevity, we present full estimation details in the Supporting
Information (S1 and S2).
3.1.2. Summarising discrimination for clinical practice. When reporting results from model (1),
researchers typically focus on the summary estimates of sensitivity and specificity, obtained by
exp(𝛽1)/[1 + exp(𝛽1)] and exp(𝛽0)/[1 + exp(𝛽0)], respectively, and their CIs (or joint confidence region)
[2]. However, because of heterogeneity, these summary results may be misleading as they do not nec-
essarily reflect the test’s sensitivity and specificity when applied to particular populations. We therefore
suggest that researchers should also calculate and report
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(1) a prediction region for the true sensitivity and specificity in a new population [2], such as a 95%
prediction region; and
(2) the probability that the true sensitivity and specificity will both be above some clinically acceptable
values in the new population.
These measures reveal the potential impact of heterogeneity on discrimination performance in new
populations and thereby help indicate whether a test is fit for purpose. For example, if both sensitivity and
specificity need to be at least 90% for the test to be considered useful, there should be a large probability
that sensitivity and specificity will both meet this criteria in a new population. To make these inferences
following estimation of model (1), the joint predictive distribution for a new pair of sensitivity and speci-
ficity needs to be derived. If 𝛽1, 𝛽0, 𝜏
2
1 , 𝜏
2
0 and 𝜌 were known, then this distribution on the logit-scale
would be (
logit
(
p1i
)
NEW
logit
(
p0i
)
NEW
)
∼N
[(
𝛽1
𝛽0
)
, 𝛀
]
, 𝛀 =
(
𝜏21 𝜏1𝜏0𝜌
𝜏1𝜏0𝜌 𝜏
2
0
)
(2)
However, these parameters are not known, and so the predictions should also account for their uncertainty.
This is most natural in a Bayesian framework [8], where the uncertainty in all parameters estimated in
model (1) is propagatedwhen deriving predictions for new sensitivities and specificities. For our Bayesian
application of model (1) in this paper, vague prior distributions ofN (0, 100 000)were specified for 𝛽1 and
𝛽0, and a Wishart prior distribution for𝛀−1 (Supporting Information S2). However, alternative priors for
the components of𝛀 are also possible [21,22]. During the Bayesian estimation, posterior inferences about
logit
(
p1i
)
NEW
and logit
(
p1i
)
NEW
canmade by sampling from their joint posterior (predictive) distribution
to calculate 95% intervals and regions, and joint probability statements.
In a frequentist framework, a bivariate t-distribution with k − 2 degrees of freedom might be used
to approximate the joint predictive distribution, which extends the frequentist use of a univariate t-
distribution to derive a prediction interval for a single measure [8, 9]. For example, a prediction interval
for logit
(
p1i
)
NEW
is
𝛽1 − tk−2
√
𝜏21 + Var(𝛽1), 𝛽1 + tk−2
√
𝜏21 + Var(𝛽1) (3)
where Var(𝛽1) is the variance of 𝛽1 and tk−2 is the 100(1− 𝛼∕2) percentile of the t-distribution with k− 2
degrees of freedom, with 𝛼 usually chosen as 0.05 to give a 95% prediction interval. A t-distribution,
rather than a normal distribution, is used to help account for the uncertainty in 𝜏21 .
3.2. c Statistic
Tests measured on a continuous scale (such as PTH) allow sensitivity and specificity to be estimated at
each of multiple thresholds to define test positive and test negative and thus produce an ROC curve. In
this situation, a measure of the test’s discrimination across all thresholds is the area under the ROC curve,
otherwise known as the c statistic [23]. This gives the probability that, if one diseased person and one
non-diseased person were chosen at random, the continuous test value would be larger for the diseased
person. Given multiple studies, Van Klaveren et al. [24] propose that a random-effects meta-analysis of
the c statistic estimates is useful:
ci ∼ N(𝜃i, s2i )
𝜃i ∼ N(𝜇c, 𝜏2c )
(4)
Here, ci is the c estimate in study i assumed to have an (approximate) normal sampling distribution with
its variance, s2i , assumed known and its mean, 𝜃i, the true c statistic in study i, which itself is assumed
drawn from a normal distribution with summary mean 𝜇c and between-study variance 𝜏
2
c . When the raw
test data are available from each study, the ci can easily be obtained using standard statistical packages,
and most typically, bootstrapping can be used to obtain the s2i required. Model (4) can be estimated in a
frequentist framework, for example, using methods of moments or restricted maximum likelihood, and
the 95% prediction interval is then derived using
?̂?c − tk−2
√
𝜏2c + Var(?̂?c), ?̂?c + tk−2
√
𝜏2c + Var(?̂?c) (5)
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2015, 34 2081–2103
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Figure 1. Confidence and prediction regions following application of model (1) to the temperature data.
where Var(?̂?c) is the variance of ?̂?c and other terms follow as outlined in Equation (3). In a Bayesian
framework, (vague) prior distributions are required, such as 𝜇c ∼ U (0.5, 1) and 𝜏c ∼ U (0, 0.25), and then
probability statements about the potential c statistic in a new population can obtained from the posterior
distribution for 𝜃iNEW , such as the probability that the c statistic will be above 0.9.
3.3. Application
3.3.1. Ear temperature for diagnosis of fever. Model (1) was fitted to the 11 studies evaluating an ear
temperature ⩾38.0 °C for identifying fever in children (Table I). The frequentist results are displayed
in Figure 1 and are very similar to the results from a Bayesian approach, which we now discuss. The
summary sensitivity is 0.65 (95% CrI: 0.51 to 0.77) and the summary specificity is 0.98 (95% CrI: 0.96
to 0.99). The summary specificity is high, so those without fever are usually correctly classed as nega-
tive (<38.0 °C). However, the summary sensitivity is low, indicating that many children with fever are
not classed as positive (⩾38.0 °C). Furthermore, despite the same ear thermometer manufacturer (first-
temp), a consistent threshold (38.0 °C) and a common reference standard (rectal temperature), there is
considerable between-study heterogeneity in both sensitivity and specificity. This is illustrated by the
wide prediction region within Figure 1. A 95% prediction interval for sensitivity in a new population is
calculated as 0.21 to 0.94 and for specificity is calculated as 0.89 to 1. Direct probabilistic statements
can also be made from the (joint) predictive distribution for a new sensitivity and specificity (Supporting
Information S3). For example, in a new population, the probability that sensitivity will be over 80% is
0.19, and the probability that specificity will be over 80% is 0.99. Further, the joint probability that in a
new population both sensitivity and specificity will be >80% is just 0.19 (Figure 1). Hence, if sensitivity
and specificity above 80% are deemed the minimum acceptable, there is less than a one in five chance
that ear temperature will be adequate within a new population. So there is little evidence here to suggest
that ear temperature can replace rectal temperature as an acceptable technique for assessing fever.
3.3.2. PTH for predicting hypocalcaemia. Parathyroid is measured on a continuous scale, and as the raw
data were available to us, we calculated the c statistic and its 95% CI and bootstrap standard error for
each of the five studies. Model (4) was then estimated using methods of moments [25], and the results
are shown in the Supporting Information (S4) for the test relating to the % change in PTH from baseline
2086
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2015, 34 2081–2103
R. D. RILEY ET AL.
to 0–20 min post-surgery. The summary c statistic is encouragingly high (0.92, 95% CI: 0.86 to 0.97).
Furthermore, although there is heterogeneity in discrimination performance across studies (I2 = 28%),
the 95% prediction interval derived from Equation (5) indicates that c in a new population will be between
0.78 and 1.00, and is thus also predominately high. Bayesian inferences were similar, but the width of
intervals were sensitive to the prior distribution for the between-study variance. However, for all the
priors considered, there was a probability of about 0.89 that c in a new population will be above 0.8 and
a probability of 0.59 that it will be above 0.9. Therefore, there is large probability that PTH measured at
0–20 min will have very good discrimination when applied in new populations. The discrimination was
similar when PTH was measured 1–2 h post-surgery.
For implementation of PTH in clinical practice, a single threshold would be chosen to define test
positive and negative. Noordzij et al. [7] recommend a threshold of a 65% change in PTH from pre-
surgery to 1–2 h post-surgery, for which Bayesian estimation of model (1) gives a summary sensitivity of
0.93 (95% CrI: 0.83 to 0.99) and a summary specificity of 0.81 (95% CrI 0.71 to 0.89). The probability
that sensitivity will be greater than 0.8 in a new population is 0.96, and for specificity it is 0.59 (Supporting
Information S3). The probability that both will be above 0.8 is 0.57. In other words, we expect that in
nearly 6 out of 10 populations, both the sensitivity and specificity of the PTH test will be above 0.8.
Thus, PTH measured at 1–2 h appears to have high discrimination for potential clinical use, and this is
evaluated further in terms of post-test predictions in Section 4.3.
4. Examining and summarising the calibration of post-test probabilities derived
following meta-analysis
In practice, clinicians are more interested in PPV and NPV, the post-test disease (outcome) probabili-
ties conditional on knowing the test result. Following meta-analysis, an explicit strategy (or statistical
equation) is therefore needed to tell clinicians how to derive PPV and NPV in their population. Further,
any recommended strategy or equation should be formally evaluated in new data, a concept known as
external validation in the prediction modelling field [26]. Thus, in this section, we consider (i) strate-
gies for deriving PPV and NPV in new populations using existing meta-analysis results, and then (ii) an
approach called internal–external cross-validation [27, 28], which allows the strategies to be examined
and compared in terms of calibration of predicted and observed PPV and NPV.
4.1. Strategies to derive PPV and NPV in new populations
For simplicity, let us focus on prognostic test studies, as these are usually cohort studies for which absolute
risk can be observed [29]. Let there be n1i and n0i patients that do and do not have an outcome by a
particular time, respectively, and let r11i be the number of patients in study i who had the outcome and a
positive test result at baseline, and r00i be the number of patients in study i who did not have an outcome
and had a negative test result at baseline. We now suggest three possible strategies for deriving PPV and
NPV in a new population (L), given k existing studies for meta-analysis.
4.1.1. Modelling option A: use summary values of sensitivity, specificity and prevalence. The simplest
approach is to derive the new PPV and NPV by first obtaining meta-analysis summary estimates of sen-
sitivity, specificity and prevalence, and then plugging them into the well-known Bayes theorem solutions
for deriving PPV and NPV from sensitivity, specificity and prevalence:
PPVnewL =
sensitivityMA × prevalenceMA
[sensitivityMA × prevalenceMA] + [(1 − specificityMA)(1 − prevalenceMA)]
(6)
NPVnewL =
specificityMA × (1 − prevalenceMA)
[(1 − sensitivityMA) × prevalenceMA] + [specificityMA × (1 − prevalenceMA)]
(7)
In these equations, ‘MA’ denotes the summary meta-analysis value, and ‘new’ denotes the predicted
value in the new population, L. This approach mimics situations where nothing is known about test accu-
racy performance and prevalence in the new population, and so one simply takes the summary values from
existing studies. The summary sensitivity and summary specificity can be obtained from fitting model
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2015, 34 2081–2103
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(1) to the available studies (which may include cohort and case-control studies), and the summary preva-
lence can be obtained from a meta-analysis of available cohort studies, for example, by using maximum
likelihood to fit:
n1i ∼ Binomial
(
Ni, prevalencei
)
logit(prevalencei) ∼ N
(
𝛼, 𝜏2
𝛼
) (8)
whereNi is the total sample size in study i and the summary prevalence is obtained by exp(?̂?)∕(1+exp(?̂?)).
4.1.2. Modelling option B: use summary values of sensitivity and specificity, and known prevalence in the
intended population. Even when there is no between-study heterogeneity in sensitivity and specificity,
it is likely that there is heterogeneity in the prevalence. Thus, PPV and NPV can be tailored to partic-
ular populations by adapting Equations (6) and (7) by including the prevalence in the new population
of interest:
PPVnewL =
sensitivityMA × prevalenceL
[sensitivityMA × prevalenceL] + [(1 − specificityMA)(1 − prevalenceL)]
(9)
NPVnewL =
specificityMA × (1 − prevalenceL)
[(1 − sensitivityMA) × prevalenceL] + [specificityMA × (1 − prevalenceL)]
(10)
where prevalenceL is the known prevalence in the intended population. If this prevalence is unknown, it
might be substituted by the observed prevalence from a sample of patients from the intended population,
to use as a proxy for the true prevalence.
4.1.3. Modelling option C: fit a bivariate meta-analysis of PPV and NPV, with prevalence as a covariate.
Rather than deriving PPV and NPV by considering sensitivity and specificity independent of prevalence,
a more sophisticated option is to consider sensitivity, specificity and prevalence jointly. Chu et al. [30]
propose a trivariate meta-analysis for this purpose. However, in our experience, it is difficult to esti-
mate reliably the two between-study correlations in this model. Thus, we take the approach suggested by
Leeflang et al. [5], where PPV and NPV (rather than sensitivity and specificity) are now the two mea-
sures of interest, and a covariate included for prevalence. This bivariate meta-regression is applied to the
available cohort studies in the meta-analysis and can be written as
r11i ∼ Binomial
(
n+i,PPVi
)
r00i ∼ Binomial
(
n−i,NPVi
)(
logit
(
PPVi
)
logit
(
NPVi
) )∼N[( 𝛿1 + 𝛾1prevalencei
𝛿0 + 𝛾0prevalencei
)
, 𝛀
]
, 𝛀 =
(
𝜏2PPV 𝜏PPV𝜏NPV𝜌
𝜏PPV𝜏NPV𝜌 𝜏
2
NPV
) (11)
Here, n+i and n−i denote the number who tested positive and negative, respectively, in study i. The model
specifies that the true logit(PPVi) and logit(NPVi) in each study depends on the prevalence (prevalencei)
of that study (note that an alternative specification could be to use logit(prevalencei) as the covariate,
although for brevity, this is not considered further here). It allows for unexplained between-study hetero-
geneity in logit(PPVi) and logit(NPVi), 𝜏2PPV and 𝜏
2
NPV , respectively, and their potential between-study
correlation (𝜌). A disadvantage of model (11) is that it discards studies (e.g. case-control studies) that
do not allow reliable estimation of PPV and NPV but could otherwise contribute towards sensitivity
and specificity.
Model (11) can be fitted using the same techniques as described for model (1), and the estimated
parameters enable PPV and NPV to be derived in a new population (L) if the prevalence (prevalenceL) in
the intended population is specified, as follows:
PPVnewL =
exp(𝛿1 + ?̂?1prevalenceL)
1 + exp(𝛿1 + ?̂?1prevalenceL)
(12)
NPVnewL =
exp(𝛿0 + ?̂?0prevalenceL)
1 + exp(𝛿0 + ?̂?0prevalenceL)
(13)
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4.2. Internal–external cross-validation for checking calibration of predicted PPV and NPV
in new populations
Whatever strategy is used to derive PPV and NPV in new populations, external validation is required to
check the calibration of predictions with observed risk. However, it is well known that calibration perfor-
mance of predictive probabilities is optimistic when they are estimated and then tested on the same data
[26, 31, 32]. Thus, to validate the chosen strategy, we suggest using internal–external cross-validation,
which omits a study from the meta-analysis that derives the prediction equations, so that calibration can
be checked in independent data. The process is then repeated, with a different study omitted in each cycle.
The approach was proposed by Royston et al. [27] and recently extended by Debray et al. [28] for valida-
tion of multivariable prediction models. We now implement it within the context of test accuracy studies
and extend it to include a meta-analysis that summarises the calibration performance across all cycles.
4.2.1. Summarising overall calibration performance. Suppose that the focus is on summarising the over-
all calibration between predicted and observed outcome risks in new populations. The internal–external
cross-validation approach proceeds as follows:
(1) Select a study L to be omitted
(2) In the remaining k − 1 studies, fit a chosen meta-analysis model and use a chosen strategy (e.g.
options A to C earlier) to produce equations for deriving PPV and NPV in a new population. Apply
these equations to the omitted study L, to calculate the predicted PPVnewL and NPVnewL.
(3) In the omitted study L, calculate the total observed (O) and the total expected (E) outcomes, where
OL = n1L
EL = PPVnewL(r11L + (n0L − r00L)) + (1 − NPVnewL)(r00L + (n1L − r11L)) (14)
where PPVnewL and NPVnewL are those calculated using the equations derived in step (2).
(4) In the omitted study, compute the overall calibration of predicted probabilities by
(OL∕EL) = (O∕E)L, and calculate ln (O∕E)L and its standard error, sL.
Defining POL = OL∕
(
n1L + n0L
)
and PEL = EL∕
(
n1L + n0L
)
, we can write
ln(O∕E)L = ln(POL∕PEL) = ln(POL) − ln(PEL),
with POL and PEL the observed and expected (O/E) proportion with the outcome in the omit-
ted study, respectively. Treating the expected proportion PEL as fixed, the standard error of
ln (O∕E)Lequals the standard error of ln(POL), which is given approximately by [33]
sL =
√
1 − POL
(n1L + n0L)POL
(15)
(5) Repeat steps (1) to (4) for each omitted study, giving a set of k values for ln(O∕E)L and sL.
(6) Perform a (frequentist or Bayesian) random-effects meta-analysis of the ln(O∕E)L values
as follows:
ln(O/E)L ∼ N
(
𝜃L, s
2
L
)
𝜃L∼ N
(
𝛽, 𝜏2
) (16)
(7) Summarise calibration across all studies by displaying the meta-analysis results using a forest plot
including the summary O/E value, its 95% CI, I2 and a 95% prediction interval for the O/E value
in a new population.
The omitted studies in step (1) must be cohort studies (or cross-sectional studies for diagnostic tests).
Other studies, such as case-control studies, that do not provide unbiased estimates of outcome risk (or
disease prevalence for diagnostic test studies) might contribute to the developed prediction equations in
step (2) (e.g. using options A or B in Section 4.1).
Compared with previous use of the internal–external cross-validation approach [27,28], we have added
the meta-analysis component in steps (6) and (7). Because uncertainty in each ratio O/E reflects only
within-study error for the omitted study and not the error associated with computing the expected values
from the other studies, it is appropriate to combine these across studies using the within-study errors in the
weights. This allows us to quantify whether observed differences in overall calibration are due to chance
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2015, 34 2081–2103
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or heterogeneity and to summarise calibration performance on average and in potential new populations.
Perfect calibration would be revealed by a summary O/E value of 1 (indicating perfect calibration on
average across all populations), together with no between-study heterogeneity in calibration performance,
resulting in a narrow 95% prediction interval for the O/E in a new population. Such perfection is unlikely,
and so researchers might consider what calibration performance would be acceptable. For example, a
95% prediction interval for O/E falling between 0.9 and 1.1 might be deemed acceptable, as the true risk
is then within 10% of the predicted risk in new populations. In other words, one desires a large probability
(0.95 or more) that O/E is between 0.9 and 1.1 in new population.
4.2.2. Summarising calibration of PPV and NPV separately and more exactly. The earlier analyses allow
the overall calibration to be examined, comparing the total observed outcome events across both test-
positive and test-negative individuals with the total expected number. Also of interest is the calibration
of PPV and NPV themselves, especially as one might be more clinically important than the other. For
example, in the thyroidectomy example, a reliable NPV is crucial as those with a negative PTH test may
be discharged early to release valuable resources (such as beds and clinical care) to the hospital. The
calibration of PPV and NPV can be undertaken using the same approach as described in Section 4.2.1
but with a separate O/E estimated for test-positive and test-negative patients in each study, followed by a
separate meta-analysis of O/E for each.
However, when considering NPV (or PPV) separately, it is increasingly likely that some studies will
have no events (or no non-events) for test-negative (or test-positive) patients. In such studies, the standard
error of ln(O∕E)L cannot be derived using Equation (15) as POL is 1 (or 0), and thus, meta-analysis model
(16) is problematic. A more exact meta-analysis is thus proposed, which models the binomial likelihood
directly in each study to avoid having to derive standard errors and thereby accommodate studies with
zero events (or zero non-events) [13]. Without loss of generality, consider just PPV so that the analysis
includes only test-positive (‘+’) patients. The model is written as
r11L ∼ Binomial
(
n+L,PPVL
)
logit(PPVL) = 𝛼L + logit
(
PPVnewL
)
𝛼L ∼ N
(
a, 𝜏2
𝛼
) (17)
where logit
(
PPVnewL
)
is an offset term corresponding to the logit of the predicted PPV for study L
obtained from step (2). n+L is the total number of test-positive patients in study L, and r11L is the number
of those who truly have the outcome. The 𝛼L are often referred to as the calibration-in-the-large [26], and
so the estimate of a provides the summary calibration-in-the-large. A more formal interpretation is that a
is the average log odds ratio, summarising the log of observed to expected odds across studies. A value of
0 thus indicates perfect calibration. The heterogeneity, 𝜏2
𝛼
, is the between-study variation in calibration,
and this will be zero if calibration performance is consistent across all populations. Model (17) can be
fitted in either a Bayesian or a frequentist framework (Supporting Information S5 and S6), with posterior
(predictive) inferences then derived. For example, following frequentist estimation and given a particular
PPVnewL, an approximate 95% prediction interval for the true logit PPV is(
â − tk−2,0.975
√
𝜏2
𝛼
+ Var(â)
)
+ logit
(
PPVnewL
)
,
(
â + tk−2,0.975
√
𝜏2
𝛼
+ Var(â)
)
+ logit
(
PPVnewL
)
(18)
The lower and upper bounds can then be transformed back to the PPV scale, or the O/E scale, as desired.
4.3. Applications
We now apply the internal–external cross-validation approach to the two examples introduced in
Section 2. The results are summarised in Tables IV–VII, and Figures 2–5.
4.3.1. Ear temperature for diagnosis of fever. In Section 3, the meta-analysis revealed that ear tempera-
ture above or below 38 °C only moderately discriminated those with and without fever. We now use the
internal–external cross-validation approach to evaluate the calibration of post-test probabilities, PPV and
NPV, derived using options A to C. The results at each cycle of the procedure are given in Table IV for
each strategy, and Figure 2 and Tables V and VI summarise calibration performance.
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Overall calibration.First consider the overall calibration of observed to expected values, across all
patients, for the case where PPV and NPV are derived by option A (use the summary sensitivity, speci-
ficity and prevalence frommeta-analysis of the other studies) (Table IV). The predicted PPV and NPV are
close to 0.97 and 0.77 for most studies (Table IV). Frequentist estimation of meta-analysis model (16),
using methods of moments, gives a summary O/E close to 1 with a narrow CI (summary O/E = 1.02, 95%
CI: 0.95 to 1.10), suggesting excellent calibration on average in new populations (Figure 2(a); Table V).
However, there is heterogeneity in calibration performance (I2 = 51%), a likely consequence of the het-
erogeneity in sensitivity and specificity identified in Section 3. A 95% prediction interval for the O/E in
a new population is 0.85 to 1.24, suggesting that the true fever risk will be between 24% higher and 15%
lower than that expected in new populations. Bayesian estimation gives similar inferences, although with
wider intervals, and there is a probability of 0.66 that 0.9 < O/E < 1.1 (Table V), and so in two-thirds of
populations, calibration will reassuringly be within 10% of that predicted.
Interestingly, calibration appears worse when the internal–external validation approach is repeated
with PPV and NPV calculated using option B (prevalence taken from the omitted study’s population,
combined with summary sensitivity and specificity). As true population prevalences were unknown
in omitted studies, we mimicked this situation by assuming the observed prevalence in the omitted
study was actually the true prevalence. The forest plot summarising O/E for this approach is shown in
Figure 2(b). Compared with the previous analysis, heterogeneity in calibration performance increases
(I2 = 62%), and thus, the 95% prediction interval is wider (0.81 to 1.30). Therefore, post-test predic-
tions appear less reliable using option B rather than option A. Option C (bivariate meta-regression of
PPV and NPV on prevalence) performs similarly to option A. The summary O/E is slightly improved
(1.01), but there is additional heterogeneity (I2 = 56%), and thus, the 95% prediction interval is similar
(0.82 to 1.25).
Calibration of PPV. Because of NPV being too low to rule out fever, one might examine just the cali-
bration of PPV. Using option A to derive PPV in new populations, the predicted PPV is close to 0.97 in
all cycles of the internal–external cross-validation approach (Table IV). Some studies did not have any
test-positive children without fever, and thus, the exact meta-analysis model (17) was used. Maximum
likelihood estimation gives a summary calibration, a, of 0.015 (95% CI: −0.75 to 0.78) (Table VI). This
reveals that, on average, there is close to perfect agreement between expected and observed PPVs in
the studies. However, there is heterogeneity (𝜏𝛼 = 0.70) in calibration performance, which, when using
Equation (18) followed by back transformations, corresponds to a 95% prediction interval of 0.87 to 1.03
for the O/E in a new population where the predicted PPV was 0.97. Bayesian estimates are very similar
(Table VI), and there is a large probability of 0.98 that O/E will be between 0.9 and 1.1 in a new popula-
tion. Further, for a predicted PPV of 0.97, there is a probability of 0.78 that the true PPV will be between
0.95 and 1. The calibration between observed and predicted PPVs using option A is shown in Figure 4(a).
Calibration performance is not improved when deriving PPV using options B or C (results not shown),
as either the summary calibration performance is worse or the heterogeneity is larger.
Thus, PPV derived from option A appears to calibrate extremely well in new populations. We thus
derived a final PPV from option A to be used in clinical practice, obtained by placing into Equation (6)
the summary estimates of sensitivity, specificity and prevalence from the meta-analyses of all 11 studies.
This gave a high PPV of 0.97, and thus, an ear temperature ⩾38.0 °C strongly indicates that a child truly
has a fever.
4.3.2. PTH for predicting hypocalcaemia. Section 3.3 identified that PTH has high sensitivity and speci-
ficity at a threshold of 65% when PTH is measured 1–2 h post-surgery (summary sensitivity, 0.93 and
summary specificity, 0.81). For this test, we now use the internal–external cross-validation approach to
examine and compare the calibration of PPV and NPV in new populations as derived from options A and
B. Given there were only five studies in the meta-analysis, the meta-regression approach of option C was
not deemed sensible and is thus not evaluated here.
Overall calibration.NPV and PPV are both estimated consistently high during the internal–external
cross-validation process (Table VII). When post-test probabilities are based on option A (using the sum-
mary sensitivity, specificity and prevalence), frequentist estimation of model (16) indicates there is no
heterogeneity in calibration performance (I2 = 0%) (Figure 3(a)). The summary O/E is 1.07, suggest-
ing under-prediction of hypocalcaemia events in new populations. When the post-test probabilities are
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Figure 2. Meta-analysis of the observed/expected (O/E) calibration statistics (frequentist estimation of model
(16)) from the internal–external cross-validation approach applied to the ear temperature data for diagnosis of
fever. PPV, positive predictive value; NPV, negative predictive value.
derived using option B (summary sensitivity and specificity, combined with observed prevalence in omit-
ted study), there continues to be no heterogeneity, but the summary O/E is improved to 1.01, indicating
almost perfect calibration on average (Figure 3(b)). Although there is no estimated heterogeneity, the
prediction interval (0.68 to 1.50) is wide (Figure 3(b)), as it accounts for large uncertainty in the hetero-
geneity and pooled estimates, a consequence of only five studies in the meta-analysis. Bayesian posterior
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Figure 3. Meta-analysis of the observed/expected (O/E) calibration statistics (frequentist estimation of model
(16)) from the internal–external cross-validation approach applied to the parathyroid data at 1–2 h for prediction
of hypocalcaemia. PPV, positive predictive value; NPV, negative predictive value.
estimates are very similar, although intervals are even wider. There is a probability of only 40% that the
true O/E is between 0.9 and 1.1, again reflecting the large uncertainty in the meta-analysis.
Calibration of NPV.As mentioned, the pivotal element for the PTH test is good calibration for NPV
so that patients are not wrongly discharged from hospital. Table VII shows that the predicted NPV is
consistently high in the cycles of internal–external cross-validation, ranging from 0.96 to 0.98 when the
summary prevalence is used (option A) and from 0.95 to 0.99 when the observed population prevalence is
used (option B). To examine calibration performance of predicted NPV in new populations, meta-analysis
model (17) was applied to accommodate studies that had no test-negative patients with hypocalcaemia.
For predicted NPV derived using option B, the summary calibration, a, is 0.093 following frequentist
estimation, which suggests only a small positive miscalibration between observed and predicted NPVs.
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Figure 4. Calibration of predicted and observed post-test probabilities, for (a) positive predictive value (PPV)
derived using option A in the temperature example and (b) negative predictive value (NPV) derived using option
B in the parathyroid example. Each circle represents a study and is proportional to the study sample size.
There is also no estimated heterogeneity in calibration performance. For a predicted NPV of 0.95, these
results correspond to a 95% prediction interval for the true NPV in a new population of 0.78 to 0.99, or
an O/E of 0.87 to 1.03. These intervals are wide because of the small number of studies. For the same
reason, Bayesian estimation is especially sensitive to the choice of prior distribution for 𝜏, and frequentist
and Bayesian results are less similar here than for the temperature analyses (Table VI). However, the
Bayesian approach agrees that option B gives well-calibrated NPVs in new populations. For example,
when using a U(0,1) prior for 𝜏, there is a large probability of 0.95 that option Bwill give a predicted NPV
that calibrates within 10% of the true NPV in a new population (Table VI). The calibration of observed
and predicted NPVs is shown in Figure 4(b). Predictive (posterior) distributions for the NPV and O/E in
a new population are shown in Figure 5. Option A performs very similarly to option B.
Thus, although further studies would be useful to reduce the width of prediction intervals, the current
evidence strongly suggests that option B (or even A) will give predicted NPVs that calibrate well in new
populations. Using option B and deriving summary sensitivity and specificity from a meta-analysis of all
5 studies, the final prediction equation for a new NPV is
NPVnewL =
0.81 × (1 − prevalenceL)
[(1 − 0.93) × prevalenceL] + [0.81 × (1 − prevalenceL)]
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Figure 5. Posterior distributions for the true observed/expected (O/E), positive predictive value (PPV) or negative
predictive value (NPV) in a new population, derived from Bayesian estimation of model (17).
5. Extensions
We now briefly consider two potentially useful extensions of our work.
5.1. Comparing test performance
The examination of calibration and discrimination performance in new populations is also a novel way to
compare the performance of two different tests, or for comparing the same test at different thresholds or
measurement methods. For example, in the PTH example, there are two competing tests: PTH measured
at 0–20 min or at 1–2 h. Both have a high discrimination indicated by c statistics above 0.80 (see, e.g.
Supporting Information S4), but which will perform better in new populations? For illustration, we now
evaluate this for a threshold of 65%.
5.1.1. Comparison of sensitivity and specificity at a 65% threshold. For PTH at 0–20 min, fitting model
(1) in a Bayesian framework gives a summary sensitivity of 0.82 (95% CI: 0.64 to 0.94) and a summary
specificity of 0.79 (0.67 to 0.89). The probability that sensitivity will be greater than 0.8 in a new popula-
tion is 0.60, and for specificity, it is 0.44. The probability that both will be above 0.8 in a new population
is just 0.20. In contrast, recall that for PTH measured at 1–2 h, there was a probability of 0.57 that both
would be above 0.8 in a new population, because of the larger summary sensitivity (0.93) and specificity
(0.81). Thus, the discrimination of the test is substantially better when measured at 1–2 h.
5.1.2. Comparison of the calibration of post-test probabilities at a 65% threshold. At 0–20 min post-
surgery, the internal–external cross-validation approach suggests that NPV is consistently predicted to be
above 0.90, whereas PPV is much lower (Table VII). Higher NPV and PPVs are generally predicted at
1–2 h (Table VII), because of the larger sensitivity and specificity, and thus are clearly preferred if they
calibrate well in new populations.
When using option B to derive post-test predictions, at 0–20 min the summary O/E frommeta-analysis
model (16) is 0.96, which suggests the test slightly over-predicts hypocalcaemia events, and the 95%
prediction interval is wide (0.61 to 1.50). In contrast, at 1–2 h post-surgery, the summary O/E was better
at 1.01, and the 95% prediction interval was slightly narrower (0.68 to 1.50), although still wide.
Thus, in terms of both discrimination and calibration performances in new populations, the PTH test
measured at 1–2 h appears preferable based on the evidence available.
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5.2. Predictions involving additional study-level and patient-level covariates
We suggested options A to C as possible strategies to derive post-test predictions in new populations,
based on the existing meta-analysis results. If internal–external cross-validation indicates these are all
unsuitable, for example, because of poor calibration of predictions in new populations, then further
strategies are needed to tailor predictions more accurately. For example, additional study-level covariates
could be included alongside prevalence in bivariate meta-regression model (11), to reduce heterogene-
ity further. Or alternatively, study-level covariates (including prevalence) could be included in a bivariate
meta-regression extension ofmodel (1), to explain heterogeneity in sensitivity and specificity, and thereby
allow sensitivity and specificity to be predicted in a new population conditional on particular covariate
values. For instance, accounting for the country of the study or the timing of the test may be included. If
individual participant data (IPD) are available, one could also develop and validate a multivariable pre-
diction model that contains the test value as a patient-level covariate, alongside multiple patient-level and
study-level variables. The use of meta-analysis to examine the performance of multivariable prediction
models is increasingly of interest [34, 35].
6. Discussion
Where heterogeneity exists, summary meta-analysis results might not be fit for purpose as test accuracy
in particular populations may differ considerably from the average performance. Meta-analysts therefore
need to be clearer about if and how their test accuracy results can be implemented in clinical practice.
In this article, we have proposed approaches to improve the reporting and translation of meta-analysis
results for use in clinical practice. We have brought together a number of existing concepts. In particular,
we suggest that meta-analysts should derive and report prediction intervals for the c statistic, sensitivity,
specificity and O/E in new populations. Probability statements should also be made about the likelihood
of acceptable test performance in new populations. Further, by omitting one study during each cycle of
estimation, we suggest using internal–external cross-validation to allow calibration of post-test probabil-
ities (PPV and NPV) to be examined in independent data on multiple occasions. This enables different
strategies for calculating PPV and NPV to be formally evaluated and compared, to identify the best
approach for deriving them in clinical practice.
Of course, the true impact of a diagnostic or prognostic test is ultimately measured on how it improves
patient outcomes [36]. This is perhaps best evaluated through a randomised trial, where one group has
access to test results and the other does not. Our framework can help prioritise which tests are worth
investment of a trial, by revealing which tests perform consistently well in new populations in terms of
discrimination and calibration of post-test probabilities.
6.1. Limitations of our work
The use of prediction intervals to summarise calibration and discrimination performance will be more
informative when most studies have a reasonable sample size, and there are a reasonable number of stud-
ies available. When there are fewer than about 10 studies, predictive distributions and regions might be
wide, as seen in the overall calibration results for the PTH test (Table V). With small numbers of studies,
the between-study variance is estimated with large uncertainty, and this will be propagated in subsequent
prediction intervals and distributions. Frequentist and Bayesian inferences may also be less similar with
few studies (see, e.g. PTH results in Table VI), as prior distributions become more informative.
Even with large numbers of studies, wide prediction intervals will arise when there is large between-
study heterogeneity in test performance. This indicates the test may be useful in some populations but not
in others, and so identifying those populations in which it works well becomes important (Section 5.2).
However, identifying the causes of heterogeneity is also problematic, as meta-regression often has low
power and is prone to ecological bias [37, 38].
Underpinning all our methods is the assumption that studies included in the meta-analysis are from
relevant populations for which the test is desired and that the reference standard for true disease (or out-
come) status is suitable in all studies. The broader the inclusion criteria (e.g. different patient pathways,
different countries and different reference standards), the more likely heterogeneity in test performance
will be identified. Between-study heterogeneity may also arise because of different methods of test mea-
surement, implicit or explicit differences in the choice of threshold and the quality (risk of bias) of the
studies [39]. This is clearly unwanted. Meta-analysis results are more applicable when studies are of
good quality and are consistent in how the test is implemented. Indeed, prediction intervals are really
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only relevant when based on studies with low risk of bias, as otherwise, they are widened to account for
additional heterogeneity due to bias. Meta-analysts might therefore use a strict study inclusion criteria
before applying the methods suggested in this paper. For brevity, we have not examined risk of bias for
the examples in this paper, but future work may revisit this for these data.
A key proposal is to use internal–external cross-validation to examine the calibration of predicted PPV
and NPV in new populations. For options B and C, these predicted values are derived in the external
validation study with use of the known (expected) prevalence in that population. However, when imple-
menting options B and C in both our applied examples, we did not know the known (expected) prevalence,
and so used the observed prevalences. As we replaced the known prevalence with the observed preva-
lence, one could argue that the findings for options B and C in our applied examples may still be optimistic
of true performance. However, given that the observed prevalence in a study should (for cohort studies)
be an unbiased estimate of the true prevalence, we think this is perhaps a minor issue, although further
research of this issue is appealing.
6.2. Related and further work
We believe that, if they are proposed for use in clinical practice, meta-analysis results about PPV andNPV
(or meta-analysis equations to derive PPV and NPV in new populations) should be externally validated
in new data. In other words, external validation is needed to independently check the reliability of post-
test probabilities in target populations. This is currently not well discussed in the test accuracy meta-
analysis literature. In contrast, in the prediction model field, the need for external validation is more
widely recognised, as calibration and discrimination of multivariable model predictions are prone to over-
optimism and may vary across populations. Indeed, in prediction model research, others have already
considered meta-analysis of discrimination and calibration statistics from multiple external validation
studies [24, 34, 35].
For test research, given data from multiple studies, we therefore proposed the internal–external cross-
validation approach to evaluate calibration in external data, to avoid over-optimism [26]. This allows
previously recommended strategies to derive PPV and NPV (e.g. based on meta-analysis models pro-
posed by Leeflang et al. [5] and Chu et al. [30]) to be formally evaluated in independent data from new
populations. We note that if one study is much larger than other studies, it is perhaps wise to always retain
it for the meta-analysis (and thus never exclude it for external validation). In this manner, each cycle of
internal–external cross-validation will retain the majority of the available data for obtaining the meta-
analysis equation to predict PPV and NPV, and so the equation is likely to be very similar in each cycle.
In related work, Willis and Hyde [10, 40] also suggest that test accuracy meta-analysis results should
be tailored to new populations. They consider a probabilistic approach to study selection using informa-
tion from the setting of interest; as such, only studies which are plausible for the setting are considered
for meta-analysis. The performance of this approach could also be evaluated using the internal–external
cross-validation framework.
An interesting issue is how to define ‘good’ discrimination and calibration performance. In our appli-
cation, we considered the probability that a test’s calibration (O/E) is between 0.9 and 1.1, and the
probability that a test’s discrimination c statistic is above 0.7 or 0.8 in new populations. Such criteria
are subjective, but probability statements such as these allow multiple tests to be compared and thereby
help identify the best test for use. Such test comparisons are best considered in the subset of stud-
ies that evaluate all the tests of interest, to ensure direct comparisons in the same sets of patients and
populations [41].
In small samples, the normal sampling distribution for ci in model (4) may be a poor approximation,
especially if ci estimates are close to 1. Other transformations may thus be considered in further work,
such as logit(ci), although van Klaveren et al. [24] conclude that the original c statistic scale is preferred.
Also, we note that the prediction intervals assume the true effects follow a (bivariate) normal distribution
across studies. The validity of this assumption requires empirical evaluation, and other more flexible
distributions may be required [42]. Finally, in our PTH example, the binary outcome was hypocalcaemia
by 48 h and was known for every patient. For other prognostic test situations, the outcome may be longer-
term and some patients may be censored before the time of interest. Thus, extension of our work to
time-to-event data is required.
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7. Conclusion
In conclusion, we have suggested approaches to improve the translation of test accuracy meta-analysis
results for clinical practice. Prediction intervals and probability statements are important ways to sum-
marise a test’s discrimination and calibration performance in new populations. Further, internal–external
cross-validation allows meta-analysts to identify a reliable strategy for how clinicians should derive
post-test probabilities in their population.
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